Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors

US7816347B2 · kind B2 · utility

Assignee

• Solvay Pharmaceuticals, GmbH · US

Inventors

• Klaus Witte · Hannover, DE
• Dieter Ziegler · Hemmingen, DE
• Matthias Straub · Schoorl, NL
• Paulus Antonius Remigius Koopman · Amstelveen, NL

Key dates

• Filing date: Dec 14, 2005
• Grant date: Oct 19, 2010
• Expiry date: Dec 23, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).